Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

red by the SPECT total severity score, (-256 versus +13, p=0.01). Further, patients receiving 10 or more million cells showed a trend towards improvement in ejection fraction, the percentage of blood pumped out of a ventricle with each heartbeat, (+4% versus +1%); end systolic volume (-5.7mL versus -0.1mL); and infarct size, tissue death due to loss of adequate blood supply, (-10% versus -3%) at six month follow-up. No study-related significant adverse events were reported.

"We are very encouraged that our latest findings continue to show the potential for a patient's own stem cells to reduce serious long-term complications from a heart attack," said Arshed Quyyumi, M.D., FRCP, FACC, Professor of Medicine, Cardiology, at Emory University School of Medicine and the trial's principal investigator. "This study has potentially set an important dosing threshold that offers greater protection against future down-stream adverse events, with no impact on the safety profile. Importantly, the treatment regimen is such that there is no change to our standard treatment practices. We look forward to beginning a Phase II trial."

Of the 1 million heart attacks in the U.S. each year, nearly 20% are severe enough to cause ventricular remodeling. Amorcyte's patented technologies and cGMP (current good manufacturing practices) manufacturing processes address the therapeutic and commercial challenges to post-MI stem cell treatment. Unlike other approaches, Amorcyte's technology has established cell product identity, purity, dose and potency, along with sterility and product shelf-life.

A previously published meta-analysis(1) of prior clinical trials, which included a cumulative 698 patients who received intracoronary autologous cell therapy after AMI, showed a significant improvement in ejection fraction, end systolic volumes, infarct size, reduction in subsequent MI's, and trends towards reduced deaths, admissions
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for ... advancing knowledge and research in reproductive medicine. In ... a seat on the executive board and will have ... , Dr. Hill has actively supported ASRM since 1984 ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , , , , , , Other important parameters for optimizing electroporation. , , ... Field strength , , ... field pulses , Adjustment , ... of DNA/RNA , Influence , ...
... , , Dr. Frank Stahl , ... (Society for Biotechnological Research) , , , , , ... DNA microarrays are a key technology in modern molecular biotechnology. , ... of complex genetic changes, thereby enabling a deeper insight ...
... , , Note: Genomic DNA is fragile. High molecular weight DNA ... tips or equipment when , pipetting genomic DNA. Do not vortex ... Place a 1 cm tail sample into a 1.5 ml microcentrifuge tube; ... To minimize possible cross-contamination, , do not ...
Cached Biology Technology:Optimizing electroporation parameters 2Optimizing electroporation parameters 3Optimizing electroporation parameters 4Optimizing electroporation parameters 5Optimizing electroporation parameters 6An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 2An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 3An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 4An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 5An Optimal DNA Microarray Substrate for the Identification of Fetal , and Somatic Liver Stem Cells of the Rat 6Mouse Tail Genomic DNA Isolation Protocol(1) 2
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... , WHAT: EPA,s top scientist and the ,father of ... our nation,s first preeminent scientist and inventor Benjamin Franklin ... Philadelphia Science Festival. Park visitors and local college ... innovation and invention, and how the current generation can ...
... high-quality assisted reproduction treatment as defined by the European ... ESHRE position paper on Good clinical treatment in Assisted ... patients should be treated the same and with the ... not always the case. The Guide is based ...
... professor in the Virginia Tech Carilion Research Institute and ... and Sciences, has been invited to speak at a ... 11-12 on the security implications of advances in neuroscience. ... four-part policy study on neuroscience and society called Brain ...
Cached Biology News:ESHRE sets standards for cross-border reproductive care 2ESHRE sets standards for cross-border reproductive care 3
...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
... The MBS Satellite Thermal ... and flexible solution for medium ... The MBS combines the latest ... friendly software and PC control, ...
... The AccuSpot automates LC microfractionaction, spotting ... With the AccuSpot system, LC eluent can ... plates, in trace amounts (eg.50nl). Matrix solutions ... automatic preparation of target plated for MALDI-TOF-MS ...
Biology Products: